Utilizing Data for Policies and Cost-Effectiveness of PrEP Agents

EP: 1.Common Barriers to PrEP Therapy

EP: 2.Improving Access and Adherence to PrEP

EP: 3.The Value of PrEP as HIV Prevention

EP: 4.How to Select the Right Type of PrEP for Patients

EP: 5.A New Approval in the PrEP Therapeutic Landscape

EP: 6.Understanding the Benefits of Multiple Options for PrEP Therapy

EP: 7.Identifying the Right Patient for Injectable PrEP

EP: 8.Knowing the Ins and Outs of Injectable PrEP

Now Viewing

EP: 9.Utilizing Data for Policies and Cost-Effectiveness of PrEP Agents

EP: 10.Receiving Grade A Recommendations for Injectable PrEP and New Agents

EP: 11.The Social Determinants Affecting PrEP Use and Access

EP: 12.Enhancing Patient Education on PrEP Therapies

EP: 13.Future Opportunities to Improve PrEP Access and Management

Lynne H. Milgram, MD, MBA, CPE: The ISPOR [International Society for Pharmacoeconomics and Outcomes Research 2022 Conference] presentation discussed the results of the HPTN 084 and HPTN 083 studies showing superiority in certain vulnerable groups. That’s important to note when you’re looking at pricing. You also need to look at outcomes and efficacy, especially in a disease like this, or potentially preventing a disease like this, where there are long-term consequences. That particular document might have been more accurate in looking at the benefits of long-term injectables or long-lasting injectables compared with short-acting everyday pills. The biggest takeaway is probably looking at it more holistically and globally.

We haven’t used real-world evidence at all, but we’d be very interested in looking at real-world evidence from organizations like mine, such as Kaiser [Permanente], or even CMS [Centers for Medicare & Medicaid Services], larger data sets. But we’d be interested in looking at the offset of costs. That’s probably thinking more globally or holistically. It would be, we pay X for something, the price is X, but what does it offset? What other costs might it offset?

Real-world evidence would show us maybe less utilization of more expensive drugs, or less utilization of more expensive inpatient services, imaging, or laboratory tests. We use real-world evidence because it gives us more data than at launch. Because we’re large, we might even look at our own real-world data and evidence, but that would take longer. Sometimes when we’re approached by pharmaceutical companies that have clinical trial data, they also have real-world evidence, whether it’s from Europe or other places, that helps us understand the real value of the new drug or medication.

Transcript edited for clarity.